Nanomix, which specializes in point-of-care diagnostics, has submitted an emergency use authorization request to the U.S. Food and Drug Administration (FDA) for the eLab COVID-19 rapid antigen test, according to a company press release.
The assay runs on the portable Nanomix eLab analyzer, which provides results in just 15 minutes and can be used in a wide range of settings, including hospitals, nursing homes, assisted living facilities, urgent care centers, and emergency medical care.The assay uses a nasal swab sample that can be self-administered.
Nanomix developed the COVID-19 antigen assay in part with funding from Biomedical Advanced Research and Development Authority (BARDA).
